Six-Weeks Very Low-calorie Diet (VLCD) Improves Glycaemic Control Without Reducing Plasma Branched-chain Amino Acids (BCAA) or Keto-Acids (BCKA) in Obese Men

Mariwan H Sayda

University of Nottingham

Muhammad Hariz Abdul-Aziz

University of Nottingham

Nima Gharahdaghi

University of Nottingham

Daniel J Wilkinson

University of Nottingham

Paul L Greenhaff

University of Nottingham

Bethan E Philips

University of Nottingham

Kenneth S Smith

University of Nottingham

Philip J Atherton (✉ philip.atherton@nottingham.ac.uk)

University of Nottingham

Iskandar Idris

University of Nottingham

Research Article

Keywords: Obesity, Insulin sensitivity, Amino Acids, Health

Posted Date: January 31st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1272404/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Elevated plasma leucine, isoleucine and valine (BCAA) are associated with diabetes, obesity and insulin resistance (IR). Here, we evaluated the effects of 6-weeks very-low calorie diet (VLCD) upon fasting BCAA in overweight (OW) non-diabetic men, to explore associations between circulating BCAA and IR, before and after a weight loss intervention.

Fasting plasma BCAA were quantified in an OW ($n = 26$; BMI $32.4 \pm 3 \text{ kg/m}^2$; mean age $44 \pm 9 \text{ y}$) and a normal-weight (NW) group ($n = 26$; BMI $24 \pm 3.1 \text{ kg/m}^2$; mean age $32 \pm 12 \text{ y}$). Ten of the OW group (BMI $32.2 \pm 4 \text{ kg/m}^2$; $46 \pm 8 \text{ y}$) then underwent 6-weeks of VLCD (600-800 kcal/d). Fasting plasma BCAA (gas-chromatography mass spectrometry), insulin sensitivity (HOMA-IR) and body-composition (DXA) were assessed before and after VLCD.

Total BCAA were elevated in OW individuals (sum leucine/isoleucine/valine: $457 \pm 85 \mu\text{M}$) compared to NW control individuals ($365 \pm 78 \mu\text{M}$, $P < 0.001$). Despite significant weight loss (baseline $103.9 \pm 12.3 \text{ kg}$ to $93 \pm 9.6 \text{ kg}$ and BMI $32.3 \pm 4 \text{ kg/m}^2$ to $28.9 \pm 3.6 \text{ kg/m}^2$), no changes were observed in BCAA after 6 weeks of VLCD. Moreover, although VLCD resulted in a significant reduction in HOMA-IR (baseline 1.19 ± 0.62 to 0.51 ± 0.21 post-VLCD; $P < 0.001$), Pearson's r revealed no relationships between BCAA and HOMA-IR, either before (leucine $R^2 2.49$, $P = 0.9$; isoleucine $R^2 1.2$, $P = 0.9$; valine $R^2 0.004$, $P = 0.8$) or after VLCD (leucine $R^2 0.003$, $P = 0.9$; isoleucine $R^2 0.006$, $P = 0.8$; valine $R^2 0.002$, $P = 0.7$).

Plasma BCAA are elevated in OW compared to NW individuals. However, while 6-weeks VLCD reduced body weight and IR in OW individuals, this was not associated with reductions in BCAA. This suggests existing links between BCAA and insulin resistance in OW individuals, are more complex and are not normalised by simply losing weight.

Introduction

The global prevalence of obesity (BMI of $\geq 30 \text{ kg/m}^2$) has reached epidemic proportions and is predicted to rise from 33% in 2005 to $\sim 58\%$ by 2030 (1). Obesity is a central feature of insulin resistance (IR), a major risk factor for developing type 2 diabetes (T2DM; 2,3), whilst also being associated with adverse outcomes to multiple co-morbidities, including COVID-19 (3). Thus, novel insights into the pathophysiology of IR, and effective treatments are needed.

Branched-chain amino acids (BCAA) are diet-derived nutrients, which are established regulators of skeletal muscle proteostasis that act as critical anabolic signals [and substrates] positively regulating muscle and whole-body protein synthesis (4,5). Yet, excess circulating BCAA, and their keto-acid by-products (6,7), have been associated with adverse metabolic health; for example several studies have shown that dietary BCAA restriction (8) and pharmacological reduction of plasma BCAA's (9) can improve insulin sensitivity (IS). Over decades, studies have consistently shown that elevated blood concentrations of BCAA's are common diagnostic and prognostic features for IR and risks of T2DM, with historical (10),

and more recent data (11,12), proposing BCAA to be a root-cause of IR and dysglycaemia across liver, skeletal muscle and adipose tissue sites independent of BMI (13,14). The proposed mechanisms by which BCAA-induce insulin resistance centre upon two themes: (i) that excess dietary BCAA lead to sustained activation of mTORC1 (of which, leucine is a trigger (15)) via serine phosphorylation of insulin receptor substrate (IRS-1) and IRS-2, and that (ii) impaired BCAA metabolism results in accumulation of BCAA-metabolic intermediates which suppress insulin action resulting in lipid accumulation (11). Some studies have also shown reduced skeletal muscle expression of genes involved in BCAA metabolism in those with T2DM (16), while others have shown that insulin-resistant rats demonstrate reduced capacity for BCAA catabolism (17). Finally, work from our lab (18) has shown that treating murine C2C12 myoblasts with sodium phenylbutyrate (PB), which induces BCAA catabolism, reduces BCAA and branched-chain keto-acid (BCKA) concentrations, impairs IRS-1 signaling with concomitant increases in phosphorylation of AKT. In sum, multiple lines of evidence point to dysregulated BCAA metabolism in insulin resistant states.

However, a general limitation of this whole research area is a lack of “cause-effect” relationships between elevated BCAA and IR in overweight humans (OW) – an aspect which could be addressed in longitudinal weight loss studies tracking BCAA abundance. Of all means to induce weight loss, non-pharmaceutical approaches remain an important first step in the management of obesity and diabetes. Specifically, very low-calorie diets (VLCD) represent a safe and effective means to reduce IR with short-term (~8 week) VLCD being sufficient to normalise hepatic IR, improve β -cell function in individuals with T2DM (19) and induce remission of T2DM (20), also proving efficacious in obese (21) and adolescent populations (22). The aim of this study was to investigate relationships between fasting plasma BCAA/BCKA and insulin sensitivity (IS) following 6 weeks of VLCD in OW men. We hypothesised that BCAA would be elevated in our obese volunteers, and that ensuing weight loss and reductions in IR would be associated with a normalisation of BCAA, that would further be associated with improved IS.

Research Design And Methods

Ethical approval

This study was approved by the University of Nottingham Faculty of Medicine Ethics Committee (D/2/2006-B12092016) and complied with the 2013 Declaration of Helsinki. Informed consent was obtained from all participants prior to enrolment onto the study.

Participant characteristics

To confirm that OW individuals have increased fasting plasma BCAA concentrations, we undertook baseline measurements of OW ($n=26$, 44 ± 9 y, BMI 32.4 ± 3 kg/m²) and NW individuals ($n=26$, 32 ± 12 y, BMI 24 ± 3.1 kg/m²). The latter cohort was derived from samples obtained from participants in a previously published study from our lab (23). Of the twenty six OW individuals, $n = 10$, middle-aged men (45.9 ± 8.3 y, BMI 32.2 ± 4 kg/m²) underwent 6-weeks VLCD. Volunteers with diabetes, hypertension, respiratory or

cardiovascular disorders were excluded. Individuals were not taking any prescribed medications. Before enrolment, participants were screened by a medical questionnaire and physical examination (resting ECG, clinical blood chemistry).

Study procedures

On study days, volunteers reported to our laboratory at ~09:00h fasted (except water) from midnight. Body composition was determined by dual-energy X-ray absorptiometry (DXA; Lunar Prodigy II, GE Medical Systems) with body regions auto-processed (Encore software, GE Healthcare). Fasting blood samples were collected from the antecubital vein into lithium-heparin (for plasma) or fluoride oxalate (for glucose) vacutainers, before centrifugation at 3500rpm, at 4°C for 20 min wherein the plasma was then rapidly frozen and stored at -80°C.

Dietary Management

VLCD study participants ($n = 10$), were prescribed a meal replacement diet designed to aid in weight management (Lighter Life, Harlow, Essex, U.K). This consisted of 4 meals per day, providing ~600kcal/day, with an allowance for an extra 200kcal/day in the form of fruit, vegetables or meat. The meals provided approximately 50g protein, 50g carbohydrate and 17.3g fat, complete with 100% RDA of vitamins and minerals.

Analytical methods

To determine plasma BCAA and BCKA concentrations, samples were spiked with internal standards (Norleucine and α -Ketovaleric acid) and prepared according to our routine methods (15)(15). Briefly, plasma protein was precipitated in 100% ice-cold ethanol, then pelleted by centrifugation at 10,000 rpm for 3 min at 4°C; the supernatant was dried under N_2 at 90°C in a Techne Dri-Block. The Quinoxalinol derivative of the BCKA and KVA (internal standard) were prepared using acidified 0.15% *ortho*-phenylenediamine (OPD) in 1.3M HCl, at 90°C for 60 min, then allowed to cool. Lipids and the BCKA-quinoxalinol derivatives were removed by extraction into ethyl acetate. The ethyl acetate layer and the remaining aqueous layer (containing the BCAA), were dried down separately and the N-tert-butyldimethylsilyl-N-methyl-trifluoroacetamide (MTBSTFA) derivatives of each fraction (BCKA and KCAA) were prepared and their concentrations were then determined separately by GC-MS. This involved using selected ion-monitoring (SIM) approaches, monitoring m/z 288 (Val), 302 (Leu, Ile and Norleu), and m/z 245 (KIV and KVA) and 259 (KIC and KMV). Concentrations of plasma BCAA and BCKA were determined with reference to a standard curve of known concentrations. A pooled plasma quality control (QC) sample (study-specific sample) was prepared and analysed throughout each batch to monitor instrument performance.

GC-MS conditions

Approximately 0.5 μ l of each fraction was injected into an ISQ Trace 1300 single quadrupole GC-MS (ThermoFisher Scientific, Hemel Hempstead, UK). Split injection mode (1:10) was used, with an initial

oven temperature of 100°C, held for 1min, then ramped at 12°C/min to 300°C, held for 5 min to ensure elution of higher boiling comploinds. Helium was the carrier gas at a flow rate of 1.5 mL/min, and separation was achieved on a 30 m Rxi-5MS (0.25mm internal diameter, 0.25µm thickness) fused-silica column (Restek, Bellafonte, Pennsylvania).

Insulin and glucose concentrations

Plasma insulin and glucose, were assessed in duplicate (23). Insulin was assessed via a high-sensitivity human insulin ELISA (DRG Instruments GmbH) according to manufacturer’s instructions. Glucose was measured using a clinical chemistry analyser (YSI 2950 Biochemistry analyser, YSI LifeSciences, Ohio, USA) against commercial standards. IS was calculated via HOMA-IR, according to the formula:

(fasting plasma glucose concentration (mmol.l⁻¹) x fasting plasma insulin concentration (mU.l⁻¹))/22.5

Statistical analysis

Based on normality of data or transformation where required, BCAA and BCKA concentrations were compared between OW and NW controls using Student’s unpaired *t*-test. Changes in BCAA concentrations in OW participants who underwent 6-weeks of VLCD were compared using Student’s paired *t*-test. The relationship between HOMA-IR and BCAA at baseline and following VLCD was investigated using Pearson’s correlation. All data are presented as mean ± SEM with significance at *P*< 0.05. Analyses were performed using GraphPad Prism v8.3 (La Jolla, CA, USA).

Results

Effects of VLCD on body composition and circulating BCAA levels

Six weeks VLCD elicited reductions in whole-body mass (baseline 104±12kg, post-VLCD 93±9kg; *P*<0.001) and BMI (baseline 32.2±4, post-VLCD 28.9±3.6 kg/m²; *P*<0.001), with concomitant declines in whole-body lean mass (baseline 65.2±6kg, post-VLCD 60.9±4.8; *P*<0.001), table 1.

Table 1. Changes of parameters in participants who underwent VLCD (*n* = 10), variables derived from DXA and statistical significance achieved via paired *t*-test

Variable	Baseline	Post-VLCD	Change (%)
Total body mass (kg)	103.9 ± 12.3	92.9 ± 9.6	- 10.4 (<i>P</i> <0.0001)
BMI (kg/m ²)	32.2 ± 4	28.9 ± 3.6	- 10.3 (<i>P</i> <0.0001)
Lean body mass (kg)	65.2 ± 6	60.9 ± 4.8	- 6.4 (<i>P</i> <0.0001)
Fat mass (kg)	35.3 ± 7.4	28.5 ± 6.9	- 19.7 (<i>P</i> <0.0001)

Correlation between changes in fasting BCAA’s and HOMA-IR values

VLCD reduced HOMA-IR (1.2 ± 0.62 AU, $P=0.007$; **Figure 3A**) There was no correlation between changes in HOMA-IR and BCAA at baseline (Leu, R^2 2.498e-005, $P=0.98$, Ile R^2 1.211-e006, $P=0.9$, Val R^2 0.004, $P=0.85$, sum BCAA R^2 0.001, $P=0.9$), nor following VLCD (Leu, R^2 0.003, $P=0.86$, Ile R^2 0.006, $P=0.82$, Val R^2 0.02, $P=0.65$, sum BCAA R^2 0.004, $P=0.85$), figures 3B–3E. To increase statistical power, the association between HOMA-IR and BCAA were investigated in an additional 32 individuals (total including OW participants, $N=58$) to determine if a relationship existed, however Pearson's correlation revealed no association ($R^2=0.01$, $P=0.31$, figure 3F).

Circulating BCAA in OW compared with NW volunteers

BCAA in our OW participants ($457 \pm 85 \mu\text{M}$) were higher than in NW counterparts ($365 \pm 78 \mu\text{M}$; $P<0.001$; **Figure 1D**). Despite no changes in leucine concentrations (figure 1A), these differences were driven primarily by valine (OW $253 \pm 38 \mu\text{M}$, NW $193 \pm 45 \mu\text{M}$; $P<0.001$; Figure 1C) and isoleucine (OW $70 \pm 20 \mu\text{M}$, NW $53 \pm 18 \mu\text{M}$; $P<0.001$; Figure 1B). Despite reductions in body weight, fat and lean mass, as well as HOMA-IR, plasma BCAA concentrations were largely unchanged (baseline: total BCAA $471 \pm 98 \mu\text{M}$, leucine $141 \pm 36 \mu\text{M}$; isoleucine $71 \pm 17 \mu\text{M}$ or valine $259 \mu\text{M} \pm 47$, **figure 2A–2D**) following VLCD (sum BCAA $439 \pm 75 \mu\text{M}$, $P=0.35$; leucine $131 \pm 27 \mu\text{M}$, $P=0.41$; isoleucine $76 \pm 22 \mu\text{M}$, $P=0.55$; or valine $231 \pm 32 \mu\text{M}$, $P=0.14$). Similarly, BCKA concentrations at baseline (KIC $47 \pm 18 \mu\text{M}$, KMV $22 \pm 13 \mu\text{M}$, KIV $24 \pm 14 \mu\text{M}$, sum BCKA $94 \pm 42 \mu\text{M}$) were not significantly changed following six weeks of VLCD (KIC $40 \pm 13 \mu\text{M}$ $P=0.99$, KMV $19 \pm 10 \mu\text{M}$ $P=0.63$, KIV $15 \pm 4 \mu\text{M}$ $P=0.54$, sum BCKA $75 \pm 25 \mu\text{M}$ $P=0.21$, figure 2E–H).

Discussion

We investigated relationships between plasma BCAA/BCKA concentrations and measures of IR in OW men following a 6-week low calorie dietary intervention in the form of a ~ 600 kcal/d VLCD. The magnitude of weight loss ($\sim 11\%$) was comparable to that observed in previous calorie restriction studies (~ 9.5 to 16%); (24,25) and was also accompanied by significant reductions in HOMA-IR, fat mass and lean body mass – indicative of compliance with the intervention, assuring efficacy of VLCD.

Previously, robust correlations between IR and BCAA have been well-documented (4,10,11,26), and BCAA have been proposed as prognostic biomarkers for populations at risk of developing T2DM (5). In accordance with numerous other studies (10,11,26,27), including in monozygotic twins (28), BCAA were elevated in our OW participants compared to those of a NW. Further modelling reveals that BCAA alone or in combination with other metabolites (5), such as aromatic AA (Phe/Tyr) and acylcarnitine species (11) alanine and proline (29) may hold value as metabolic 'signatures' of obesity and as predictors of T2DM. Nonetheless, relationships between plasma BCAA and other prototype metabolic 'signatures' have been shown to vary across the lifespan. For example, elevated BCAA are not associated with obesity in adolescents (30), indicating that any relationship with plasma BCAA may be context-dependant (27). Furthermore, these associations have also been shown to differ between sexes. Reflecting this, in females, it was shown that BCAA, phenylalanine, and the BCAA metabolite, 3-methyl-2-oxovalerate (31) when combined revealed the strongest associations with IR; conversely, in males it was

BCAA, alanine, proline, glutamine and aromatic AA that associated most strongly (29). Therefore, elevations in BCAA alone do not unifyingly indicate underlying metabolic dysfunction, and show variability across the lifespan and between genders.

Contrary to previous observations between food over-consumption and elevated BCAA (25), we did not observe lowering of BCAA concentrations or in BCKA, following 6-weeks of VLCD-induced weight loss. Our observations are in-line with some other VLCD studies of similar duration (32,33) but contrast to other reports of BCAA lowering induced by calorie restriction induced weight loss following bariatric surgery (34,35). While it is possible that individual subject characteristics may account for these contrasting results, other evidence suggests that reductions in BCAA occurs directly as a result of bariatric surgery *per se*, independent of weight loss. This may be due to increased BCAA catabolic gene expression in adipose tissue (36), or due to the altered AA metabolism and reduced gastric capacity following operative procedures (37,38). Therefore, while the causes of elevated plasma BCAA are not fully elucidated (i.e. the impact of age, caloric and protein intake, or impaired catabolism; (39,40)), our study suggests improvements in body composition and HOMA-IR occur independently of changes in fasting plasma BCAA. Further, a relationship between BCAA and IR was not apparent at baseline, in our OW participants, nor when we combining OW/NW cohorts ($n=58$) to increase statistical power. This illustrates the lack of simplicity of relationships between plasma BCAA and metabolic health; indeed in a previous study (41), we demonstrated that fasting BCAA positively correlated with lean mass and strength outcomes, as opposed to IR, following resistance exercise training.

Recent studies suggest a 'clogging' model of impaired BCAA catabolism, including increased accumulation of 3-hydroxyisobutyrate (3-HIB) a valine catabolite (40). These authors reported increased muscle 3-HIB secretion in IR facilitates fatty acid uptake resulting in lipid accumulation (40), a 'synergistic' relationship supported by other studies (13). Genomic markers (e.g. reduced BCAA dehydrogenase complex and its regulatory phosphatase PPM1K in obese individuals) (42,43) have also been proposed as possible mechanisms. In terms of BCAA catabolites, we measured each BCAA-derived BCKA as markers of altered BCAA metabolism. Similar to BCAA, we observed neither a change in plasma BCKA concentrations (plasma biomarkers of muscle BCAA flux) or correlations between BCKA and IS before/after VLCD. While of a preliminary nature, these findings do not support gross BCKA mis-handling in obese men. That being said, these data match those of BCAA, thus suggesting more distal metabolites (40) of BCAA metabolism may instead be implicated in tissue-level IR. Future work could adopt BCAA metabolomic and fluxomic approaches, including human muscle tissue, to address this. The lack of correlation between reductions in IR and BCAA seen herein, despite improved metabolic health i.e. significant weight/ fat loss, suggests that reductions in BCAA *per se* is not required to increase IS, but rather a metabolic reprogramming of insulin-sensitive tissue(s) in response to VLCD causes improvement in IS, preceding detectable changes in plasma BCAA's, particularly since no correlation was observed between total mass/fat loss and indices of IS.

The sample size of the VLCD cohort was a potential limitation of our study, while it may also be the 'low level' IR of participants was a confounding factor. HOMA-IR measures of ~3.5–5.5 have been reported in

obesity (11,29) compared to ~ 1.19 here. Furthermore, while VLCD elicited reductions in BMI ($29 \pm 4 \text{ kg.m}^2$; $\sim 10\%$), this improvement did not bring volunteers within the normal weight range ($\sim 25 \text{ kg.m}^2$), with longer time-frames of VLCD likely required to achieve this (44). Further, a means to mitigate the loss of lean tissue or muscle mass in interventions of this nature are important to maximise the potential therapeutic benefits, with the increased protein intake being one such option. Undoubtedly, protective factors against IR and development of obesity/ T2DM include exercise participation since direct beneficial effects on β -cell function (45) and liver function induced by exercise have been reported (46), independent of changes in body mass.

In summary, despite VLCD resulting in weight loss and improved IS and despite elevated BCAA in OW participants, neither reductions in BCAA nor correlations in BCAA/BCKA to HOMA-IR were observed following VLCD. We conclude that elevated fasting BCAA in obesity are unlikely a consequence of calorie over-consumption and are more likely to be genetically and/or metabolically programmed. Our findings do not rule out interventions aimed at driving BCAA/BCKA catabolism to improve IS in obesity/T2DM.

Declarations

Acknowledgements

The authors thank the participants who participated in this study. The authors also thank Kate Hession for assistance on study days.

Author contributions

P.J.A., K.S., I.I., B.E.P., D.J.W., and P.L.G. conceptualised the study. H.A. and N.G. performed study interventions and undertook sample collection. M.H.S., H.A. and N.G. performed laboratory analysis. M.H.S., P.J.A., K.S., B.E.P., D.J.W., and I.I., analysed and visualised the data. All contributed to drafting the manuscript and have read and agreed to the final version of the manuscript.

Funding statement

This research was supported by the MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research (grant numbers MR/R502364/1, MR/P021220/1) and the National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre. M.H.S. is funded by The National Centre for Sport and Exercise Medicine–East Midlands.

Data availability

The datasets used during the current study are available from the corresponding author on request.

Conflict of Interest

The authors declare no conflicts of interest relevant to this article.

References

1. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. *Int J Obes*. 2008;32(9):1431–7.
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract*. 2010;87:4–14.
3. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. *Diabetes Care*. 2020;43(7):1392–8.
4. Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and Insulin resistance. *Nat Rev Endocrinol*. 2014;10(12):723–36.
5. Wang, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. *Nat Med*. 2011;17(4):448–53.
6. Biswas D, Dao KT, Mercer A, Cowie AM, Duffley L, El Hiani Y, et al. Branched-chain ketoacid overload inhibits insulin action in the muscle. *J Biol Chem [Internet]*. 2020;295(46):15597–621. Available from: <http://dx.doi.org/10.1074/jbc.RA120.013121>
7. Tricò D, Prinsen H, Giannini C, De Graaf R, Juchem C, Li F, et al. Elevated α -hydroxybutyrate and branched-chain amino acid levels predict deterioration of glycemic control in adolescents. *J Clin Endocrinol Metab*. 2017;102(7):2473–81.
8. White PJ, Lapworth AL, An J, Wang L, McGarrah RW, Stevens RD, et al. Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. *Mol Metab [Internet]*. 2016;5(7):538–51. Available from: <http://dx.doi.org/10.1016/j.molmet.2016.04.006>
9. White PJ, McGarrah RW, Grimsrud PA, Tso SC, Yang WH, Haldeman JM, et al. The BCKDH Kinase and Phosphatase Integrate BCAA and Lipid Metabolism via Regulation of ATP-Citrate Lyase. *Cell Metab [Internet]*. 2018;27(6):1281-1293.e7. Available from: <https://doi.org/10.1016/j.cmet.2018.04.015>
10. Felig, Marliss E, Cahill GF. Plasma Amino Acid Levels and Insulin Secretion in Obesity. *N Engl J Med*. 1969;1(9):39–42.
11. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, et al. A Branched-Chain Amino Acid-Related Metabolic Signature that Differentiates Obese and Lean Humans and Contributes to Insulin Resistance. *Cell Metab [Internet]*. 2009;9(4):311–26. Available from: <http://dx.doi.org/10.1016/j.cmet.2009.02.002>
12. Tobias DK, Mora S, Verma S, Billia F, Buring JE, Lawler PR. Fasting status and metabolic health in relation to plasma branched chain amino acid concentrations in women. *Metabolism [Internet]*. 2021;117:154391. Available from: <https://doi.org/10.1016/j.metabol.2020.154391>
13. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. *Cell Metab [Internet]*. 2012;15(5):606–14. Available from: <http://dx.doi.org/10.1016/j.cmet.2012.01.024>

14. Kubacka J, Cembrowska P, Sypniewska G, Stefanska A. The association between branched-chain amino acids (Bcaas) and cardiometabolic risk factors in middle-aged caucasian women stratified according to glycemic status. *Nutrients*. 2021;13(10).
15. Wilkinson DJ, Hossain T, Hill DS, Phillips BE, Crossland H, Williams J, et al. Effects of leucine and its metabolite β -hydroxy- β -methylbutyrate on human skeletal muscle protein metabolism. *J Physiol*. 2013;591(11):2911–23.
16. Hernández-Alvarez MI, Díaz-Ramos A, Berdasco M, Cobb J, Planet E, Cooper D, et al. Early-onset and classical forms of type 2 diabetes show impaired expression of genes involved in muscle branched-chain amino acids metabolism. *Sci Rep*. 2017;7(1):1–12.
17. David J, Dardevet D, Mosoni L, Savary-Auzeloux I, Polakof S. Impaired skeletal muscle branched-chain amino acids catabolism contributes to their increased circulating levels in a non-obese insulin-resistant fructose-fed rat model. *Nutrients*. 2019;11(2):1–13.
18. Crossland H, Smith K, Idris I, Phillips BE, Atherton PJ, Wilkinson DJ. Exploring mechanistic links between extracellular branched-chain amino acids and muscle insulin resistance: an in vitro approach. *Am J Physiol - Cell Physiol*. 2020;319(6):C1151–7.
19. Lim, Lim K, Hollingsworth KG, Aribisala BS. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. *Diabetologia*. 2011;54:2506–14.
20. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet* [Internet]. 2018;391(10120):541–51. Available from: [http://dx.doi.org/10.1016/S0140-6736\(17\)33102-1](http://dx.doi.org/10.1016/S0140-6736(17)33102-1)
21. Hong K, Li Z, Wang HJ, Elashoff R, Heber D. Analysis of weight loss outcomes using VLCD in black and white overweight and obese women with and without metabolic syndrome. *Int J Obes*. 2005;29(4):436–42.
22. Willi SM, Martin K, Datko FM, Brant BP. Treatment of Type 2 Diabetes in Childhood Using a Very-Low-Calorie Diet. *Diabetes Care*. 2004;27(2):348–53.
23. Phillips B, Williams JP, Greenhaff PL, Smith K, Atherton PJ. Physiological adaptations to resistance exercise as a function of age. *JCI insight*. 2017;2(17):1–16.
24. Colleluori G, Aguirre L, Phadnis U, Fowler K, Armamento-Villareal R, Sun Z, et al. Aerobic Plus Resistance Exercise in Obese Older Adults Improves Muscle Protein Synthesis and Preserves Myocellular Quality Despite Weight Loss. *Cell Metab*. 2019;30(2):261-273.e6.
25. La Vignera S, Cannarella R, Galvano F, Grillo A, Aversa A, Cimino L, et al. The ketogenic diet corrects metabolic hypogonadism and preserves pancreatic β -cell function in overweight/obese men: a single-arm uncontrolled study. *Endocrine* [Internet]. 2020; Available from: <http://dx.doi.org/10.1007/s12020-020-02518-8>
26. Siddik MAB, Shin AC. Recent progress on branched-chain amino acids in obesity, diabetes, and beyond. *Endocrinol Metab*. 2019;34(3):234–46.

27. Le Couteur DG, Ribeiro R, Senior A, Hsu B, Hirani V, Blyth FM, et al. Branched Chain Amino Acids, Cardiometabolic Risk Factors and Outcomes in Older Men: The Concord Health and Ageing in Men Project. *Journals Gerontol Ser A*. 2019;XX(Xx):1–6.
28. Pietiläinen KH, Naukkarinen J, Rissanen A, Saharinen J, Ellonen P, Keränen H, et al. Global transcript profiles of fat in monozygotic twins discordant for BMI: Pathways behind acquired obesity. *PLoS Med*. 2008;5(3):0472–83.
29. Tai ES, Tan MLS, Stevens RD, Low YL, Muehlbauer MJ, Goh DLM, et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. *Diabetologia*. 2010;53(4):757–67.
30. Mihalik SJ, Michaliszyn SF, De Las Heras J, Bacha F, Lee SJ, Chace DH, et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: Evidence for enhanced mitochondrial oxidation. *Diabetes Care*. 2012;35(3):605–11.
31. Menni C, Fauman E, Erte I, Perry JRB, Kastenmüller G, Shin SY, et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. *Diabetes*. 2013;62(12):4270–6.
32. Lips MA, Van Klinken JB, Van Harmelen V, Dharuri HK, 'T Hoen PAC, Laros JFJ, et al. Roux-en-Y gastric bypass surgery, but not calorie restriction, reduces plasma branched-chain amino acids in obese women independent of weight loss or the presence of type 2 diabetes. *Diabetes Care*. 2014;37(12):3150–6.
33. Laferrère, Teixeira J, McGinty J, Tran H, Egger JR, Colarusso A, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2008;93(7):2479–85.
34. Magkos F, Bradley D, Schweitzer GG, Finck BN, Eagon JC, Ilkayeva O, et al. Effect of roux-en-y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism. *Diabetes*. 2013;62(8):2757–61.
35. Shah, Crosslin, Haynes, Nelson S, Turer CB, Stevens RD, et al. Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss. *Diabetologia*. 2012;55(2):321–30.
36. She, Reid T, Huston S, Cooney R, Lynch C. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched chain amino acid (BCAA) metabolism. *Am J Physiol - Endocrinol Metab*. 2007;293(1):1–7.
37. Steenackers N, Gesquiere I, Matthys C. The relevance of dietary protein after bariatric surgery: What do we know? *Curr Opin Clin Nutr Metab Care*. 2018;21(1):58–63.
38. Ferreira Nicoletti C, Morandi Junqueira-Franco MV, Dos Santos JE, Sergio Marchini J, Junior WS, Nonino CB. Protein and amino acid status before and after bariatric surgery: A 12-month follow-up study. *Surg Obes Relat Dis [Internet]*. 2013;9(6):1008–12. Available from: <http://dx.doi.org/10.1016/j.soard.2013.07.004>

39. Elshorbagy AK, Samocha-Bonet D, Jernerén F, Turner C, Refsum H, Heilbronn LK. Food Overconsumption in Healthy Adults Triggers Early and Sustained Increases in Serum Branched-Chain Amino Acids and Changes in Cysteine Linked to Fat Gain. *J Nutr.* 2018;148(7):1073–80.
40. Jang C, Oh SF, Wada S, Rowe GC, Liu L, Chan MC, et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. *Nat Med.* 2016;22(4):421–6.
41. Sayda MH, Phillips BE, Williams JP, Greenhaff PL, Wilkinson DJ, Smith K, et al. Associations between Plasma Branched Chain Amino Acids and Health Biomarkers in Response to Resistance Exercise Training Across Age. *Nutrients.* 2020;12(10):3029.
42. She P, Reid TM, Bronson SK, Vary TC, Hajnal A, Lynch CJ, et al. Disruption of BCATm in Mice Leads to Increased Energy Expenditure Associated with the Activation of a Futile Protein Turnover Cycle. *Cell Metab.* 2007;6(3):181–94.
43. Wang Q, Holmes M V., Smith GD, Ala-Korpela M. Genetic support for a causal role of insulin resistance on circulating branched-chain amino acids and inflammation. *Diabetes Care.* 2017;40(12):1779–86.
44. Hammer S, Snel M, Lamb HJ, Jazet IM, van der Meer RW, Pijl H, et al. Prolonged Caloric Restriction in Obese Patients With Type 2 Diabetes Mellitus Decreases Myocardial Triglyceride Content and Improves Myocardial Function. *J Am Coll Cardiol.* 2008;52(12):1006–12.
45. Heiskanen MA, Motiani KK, Mari A, Saunavaara V, Eskelinen JJ, Virtanen KA, et al. Exercise training decreases pancreatic fat content and improves beta cell function regardless of baseline glucose tolerance: a randomised controlled trial. *Diabetologia.* 2018;61(8):1817–28.
46. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. *J Hepatol [Internet].* 2012;57(1):157–66. Available from: <http://dx.doi.org/10.1016/j.jhep.2012.02.023>

Figures

Figure 1

Comparison of individual BCAA's and sum BCAA of OW ($n = 26$; mean BMI $32.2 \pm 2.9 \text{ kg/m}^2$) volunteers to NW, age-matched controls ($n = 26$; mean BMI $25.4 \pm 3 \text{ kg/m}^2$).

Figure 2

Baseline and post-VLCD comparisons of fasting plasma BCAA, and BCKA ($n=10$).

Figure 3

HOMA-IR (3A) of individuals with obesity pre and post VLCD (A, $P = 0.01$) and correlations of HOMA-IR to individual and sum BCAA at baseline and post-VLCD (3B-3E). The baseline association between HOMA-IR and BCAA across a broader age and BMI range and mixed genders (3F) with a greater $N = 58$ are displayed. The association between HOMA IR to individual BCAA (3G-3I) and total BCAA (3J) are also displayed.